High efficiency reporter gene transfection of vascular tissue in vitro and in vivo using a cationic lipid-DNA complex

Gene Therapy

Volumn 4, Issue 2, 1997, Pages 162-171

  Keogh, M C ^a   Chen, D ^a   Lupu, F ^a   Shaper, N ^a   Schmitt, J F ^a   Kakkar, W ^a   Lemoine, N R ^a,b  

^a THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Cationic liposomes; Gene therapy; Luciferase; Tfx(TM) 50; Transfection; Vascular tissues

Indexed keywords

CATION; DNA; LIPID; LUCIFERASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CAROTID ARTERY; COMPLEX FORMATION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PLASMID; PRIORITY JOURNAL; RABBIT; REPORTER GENE; VASCULAR TISSUE;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0031051922     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300374     Document Type: Article

References (46)

1. Kadel C et al. Long-term follow up after PTCA in patients with single-vessel disease. Am Heart J 1992; 124: 1159-1169.
2. CABRI Trial Participants. First-year results of CABRI (Coronary angioplasty versus bypass revascularisation investigation). Lancet 1995; 346: 1179-1183.
3. Haudenschild CC. Pathobiology of restenosis after angioplasty. Am J Med 1993; 94: 4A-40S.
4. Casscells W, Engler D, Willerson JT. Mechanisms of restenosis. Texas Heart Inst J 1994; 21: 68-77.
5. O'Brien ER, Schwartz SM. Update on the biology and clinical study of restenosis. Trends Cardiovasc Med 1994; 4: 169-178.
6. Sawa H et al. Increased intramural expression of plasminogen activator inhibitor type I after balloon injury: a potential progenitor of restenosis. J Am Coll Cardiol 1994; 24: 1742-1748.
7. Mattsson E, Clowes AW. Current concepts in restenosis following balloon angioplasty. Trends Cardiovasc Med 1995; 5: 200-204.
8. Mazur W et al. Coronary restenosis and gene therapy. Texas Heart Inst J 1994; 21: 104-111.
9. Gibbons GH, Dzau VJ. Molecular therapies for vascular diseases. Science 1996; 272: 689-693.
10. Dzau VJ, Pratt RE. Antisense technology to block autocrine growth factors. J Vasc Surg 1992; 15: 934-935.
11. Bennett RM et al. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest 1994; 93: 820-828.
12. Wagner R. Gene inhibition using antisense oligodeoxynucleotides. Nature 1994; 372: 333-335.
13. Simons M et al. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cells accumulation in vivo. Nature 1992; 359: 67-70.
14. Chang MW et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995; 267: 518-522.
15. Ohno T et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265: 781-784.
16. Feigner PL et al. Lipofection: a highly efficient lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987; 84: 7413-7417.
17. Nabel EG, Face GP, Nabel GJ. Gene transfer into vascular cells. J Am Coll Cardiol 1991; 17: 189B-194B.
18. Stewart MJ et al. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum Gene Ther 1992; 3: 267-275.
19. Ghoumari AM et al. Gene transfer in hepatocarcinoma cell lines: in vitro optimization of a virus-free system. Gene Therapy 1996; 3: 483-490.
20. Malone RW, Felgner PL, Verma IM. Cationic-liposome mediated RNA transfection. Proc Natl Acad Sci USA 1989; 86: 6077-6081.
21. Lu D et al. Optimization of methods to achieve mRNA-mediated transfection of tumour cells in vitro and in vivo employing cationic liposome vectors. Cancer Gene Ther 1994; 1: 245-252.
22. Lewis JG et al. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci USA 1996; 93: 3176-3181.
23. Nabel EG. Gene therapy for cardiovascular disease. Circulation 1995; 91: 541-548.
24. Caplen N et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nature Med 1995; 1: 39-46.
25. Nabel GJ et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biological activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90: 11307-11311.
26. Yang Y et al. Cellular immunity to viral antigens limits Eldeleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
27. Zabner J et al. Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat Genet 1994; 6: 75-83.
28. Simon RH et al. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study. Hum Gene Ther 1993; 4: 771-780.
29. Knowles MR et al. A controlled study of adenovirus-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. New Engl J Med 1995; 333: 823-831.
30. Hug P, Sleight RS. Liposomes for the transfection of eukaryotic cells. Biochim Biophys Acta 1991; 1097: 1-17.
31. Schulick AH et al. In vivo gene transfer into injured carotid arteries: optimization and evaluation of acute toxicity. Circulation 1995; 91: 2407-2414.
32. Morishita R et al. Novel and effective gene transfer technique for study of vascular renin angiotensin system. J Clin Invest 1993; 91: 2580-2585.
33. Felgner PL, Holm M, Chan H. Cationic liposome mediated transfection. Proc West Pharmacol Soc 1989; 32: 115-121.
34. Feigner JH et al Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 1994; 269: 2550-2561.
35. Promega. Tfx™-50 reagent for the transfection of eucaryotic cells Technical Bulletin 216, 1995.
36. Duzgunes N et al. Fusion of liposomes containing a novel cationic lipid, N-(2,3(dioleoyloxy)propyl)-N,N,N-trimethylammonium: induction by multivalent anions and asymetric fusion with acidic phospholipid vesicles. Biochemistry 1989; 28: 9179-9184.
37. Labroille G, Bonnefille S, Belloc F. Tfx™-50 reagent increases the uptake of oligonucleotides by leukaemic cells. Promega Notes 1996; 56: 8-13.
38. Losordo DW et al. Use of the rabbit ear artery to serially assess foreign protein secretion after site-specific arterial gene transfer in vivo. Circulation 1994; 89: 785-792.
39. Takeshita S et al. Increased gene expression after liposome-mediated arterial gene transfer associated with intimal smooth muscle cell proliferation. In vitro and in vivo findings in a rabbit model of vascular injury. J Clin Invest 1994; 93: 652-661.
40. Pickering JG et al. Liposome-mediated gene transfer into human vascular smooth muscle cells. Circulation 1994; 89: 13-21.
41. Liu Y et al. Cationic liposome-mediated intravenous gene delivery. J Biol Chem 1995; 270: 24864-24870.
42. Chapman GD et al. Gene transfer into coronary arteries of intact animals with a percutaneous balloon catheter. Circul Res 1992; 71: 27-33.
43. Dalesandro J et al. Gene therapy for donor hearts: ex vivo liposome-mediated transfection. J Thorac Cardiovasc Surg 1996; 111: 416-421.
44. Sawa Y et al. Efficiency of in vivo gene transfection into transplanted rat heart by coronary infusion of HJV liposome. Circulation 1995; 92: 11479-11482.
45. Vieweg J et al Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 1995; 55: 2366-2372.
46. Bennett MJ et al. Cholesterol enhances cationic liposome-mediated DNA transfection of human respiratory epithelial cells. Bioscience Rep 1995; 15: 47-53.